3-Methylglutaconic Acid

3-Methylglutaconic acid (3-MGA) is a branched-chain organic acid involved in mitochondrial leucine catabolism, playing a critical role in diagnosing metabolic disorders known as 3-methylglutaconic acidurias (3-MGA-urias). 

These disorders result in elevated 3-MGA levels due to specific enzyme deficiencies or mitochondrial dysfunctions. 

There are five recognized types of 3-MGA-uria.  Type I arises from a defect in the enzyme 3-methylglutaconyl-CoA hydratase, leading to disrupted leucine metabolism and symptoms like mental retardation and seizures. 

Types II through V involve different mechanisms affecting mitochondrial function.  Barth syndrome (Type II) is characterized by cardiomyopathy and skeletal myopathy, while Costeff syndrome (Type III) involves optic atrophy and cognitive deficits. 

Type IV includes various mitochondrial defects causing cardiomyopathy and neurological impairment, and DCMA syndrome (Type V) is marked by cardiomyopathy and ataxia. 

Measuring 3-MGA levels in urine using techniques like GC-MS or NMR is essential for diagnosing these conditions and understanding their underlying mitochondrial dysfunctions.

What is 3-Methylglutaconic Acid?  [1., 2., 6.]

3-Methylglutaconic acid (3-MGA) is a branched-chain organic acid that plays a key role in several metabolic disorders collectively known as 3-methylglutaconic acidurias.  It is an intermediate in the mitochondrial leucine catabolism pathway, formed during the breakdown of the amino acid leucine. 

3-MGA accumulates in the urine (organic aciduria) when the enzyme 3-methylglutaconyl-CoA hydratase is deficient, leading to a disorder called 3-methylglutaconic aciduria type I.  In types II-V of 3-methylglutaconic aciduria, elevated 3-MGA levels result from various mitochondrial dysfunctions unrelated to leucine metabolism.

Measuring urinary levels of 3-MGA by gas chromatography/mass spectrometry (GC-MS) or nuclear magnetic resonance (NMR) spectroscopy is used to diagnose these disorders.  Abnormally high levels of 3-MGA can indicate an organic acidemia, where organic acids like 3-MGA accumulate in blood, urine, and tissues like the brain. 

The buildup of 3-MGA and related metabolites like 3-methylglutaric acid and 3-hydroxyisovaleric acid is associated with various clinical manifestations, including metabolic acidosis, developmental delays, and neurological symptoms.

Therefore, 3-methylglutaconic acid is a key diagnostic marker and pathogenic metabolite in a group of inherited metabolic disorders characterized by mitochondrial dysfunction and organic aciduria, with implications for leucine metabolism and energy production. 

Its accumulation in the body can lead to severe clinical consequences, making the accurate measurement and management of 3-MGA levels crucial in these rare but potentially debilitating conditions.

Metabolic Disorders Associated with Elevated 3-Methylglutaconic Acid Levels

3-Methylglutaconic aciduria (3-MGA-uria) encompasses a group of inherited metabolic disorders characterized by elevated urinary excretion of 3-methylglutaconic acid. There are five recognized types of 3-MGA-uria. Type I results from a defect in leucine metabolism, while types II to V are associated with various mitochondrial dysfunctions.

3-Methylglutaconic acid is an intermediate in the leucine catabolism pathway within mitochondria. In type I 3-MGA-uria, a deficiency in the enzyme 3-methylglutaconyl-CoA hydratase disrupts this pathway, leading to the accumulation of 3-MGA. 

Types II through V, including conditions like Barth syndrome and Costeff syndrome, involve different mechanisms affecting mitochondrial function, resulting in increased 3-MGA excretion.

Types of 3-Methylglutaconic Aciduria  [6.] 

3-MGA-uria Type I: 

This type is an autosomal recessive disorder resulting from a defect in leucine metabolism, specifically a deficiency in the enzyme 3-methylglutaconyl-CoA hydratase. It is characterized by elevated urinary excretion of 3-methylglutaconic acid and is associated with mental retardation, seizures, and slowly progressive leukoencephalopathy.

3-MGA-uria Type II (Barth Syndrome): 

Barth syndrome is an X-linked recessive disorder featuring cardiomyopathy, cyclic neutropenia, skeletal myopathy, and mitochondrial respiratory chain dysfunction. Patients have variable excretion of 3-MGA, and the condition often involves facial dysmorphism, cognitive difficulties, and growth deficiencies.

3-MGA-uria Type III (Costeff Syndrome): 

An autosomal recessive disorder characterized by infantile bilateral optic atrophy, extrapyramidal signs, spasticity, and cognitive deficits. It is most commonly found in individuals of Iraqi Jewish descent and is caused by mutations in the OPA3 gene.

3-MGA-uria Type IV: 

This type is heterogeneous, with patients presenting with various symptoms such as cardiomyopathy, neurological impairment, and lactic acidosis. It includes several underlying genetic defects affecting mitochondrial function, such as mutations in the TMEM70 gene, which is involved in ATP synthase biosynthesis.

3-MGA-uria Type V (DCMA Syndrome): 

Dilated cardiomyopathy with ataxia (DCMA) syndrome is an autosomal recessive condition seen in the Canadian Dariusleut Hutterite population. It involves early-onset dilated cardiomyopathy, non-progressive cerebellar ataxia, testicular dysgenesis, and growth failure, and is associated with mutations in the DNAJC19 gene.

3-Methylglutaconic Acid and Mitochondrial Function 

3-Methylglutaconic acid (3-MGA) is used as a mitochondrial amino acid marker because its elevated levels in urine are indicative of disruptions in mitochondrial function.  The different types of 3-methylglutaconic aciduria (3-MGA-uria) syndromes highlight how 3-MGA can signal various mitochondrial dysfunctions:

Mitochondrial Dysfunction Indication: [3., 6., 7.] 

Elevated urinary excretion of 3-MGA is often observed in conditions where mitochondrial energy production pathways are compromised. 

Since mitochondria are crucial for cellular energy metabolism, particularly in the breakdown of amino acids like leucine, any disruption in these processes can lead to the accumulation of intermediates such as 3-MGA.

Leucine Metabolism:  [6.]  

In the specific case of 3-MGA-uria Type I, the deficiency of the enzyme 3-methylglutaconyl-CoA hydratase, which is involved in the catabolism of leucine, leads to an accumulation of 3-MGA. 

This serves as a direct biochemical marker for defects in leucine metabolism, which are closely tied to mitochondrial function.

Mevalonate Shunt and Mitochondrial Pathways: [3.] 

In other types of 3-MGA-uria (Types II-V), 3-MGA accumulation is linked to mitochondrial dysfunction through various mechanisms, such as defects in the mevalonate shunt or other mitochondrial pathways. 

These types highlight how mitochondrial diseases can lead to increased 3-MGA due to disrupted mitochondrial enzymes and metabolic processes.

‍Diagnostic Tool:  [6., 7.] 

The measurement of 3-MGA levels in urine helps in diagnosing and monitoring mitochondrial disorders. Elevated levels of 3-MGA can guide healthcare professionals to investigate mitochondrial dysfunctions further, aiding in the identification of specific types of 3-MGA-uria or other mitochondrial-related disorders.

Laboratory Testing for 3-Methylglutaconic Acid (3-MGA)

Laboratory Test, Sample Collection and Preparation

Urine and plasma are the most commonly used specimens for this analysis. Proper sample collection, handling, and storage procedures are essential to ensure the integrity and reliability of the test results.

It is important to consult with the ordering provider prior to sample collection, as avoidance of certain foods or supplements may be recommended.  Fasting may also be recommended.

Interpretation of Results

Optimal Levels of 3-Methylglutaconic Acid

Generally, falling within reference ranges for organic acids is recommended, although for many of these organic acids, a level towards the lower end of the reference range is considered optimal.  

It is essential to consult with the laboratory company used for their recommended reference range for 3-Methylglutaconic Acid.  

One company reports the following reference range for 3-Methylglutaconic Acid:  0.38 - 2.0 mmol/mol creatinine  [4.]

3-Methylglutaconic Acid High Levels: What Does Elevated 3-Methylglutaconic Acid Mean? 

Elevated levels of 3-methylglutaconic acid (3-methylglutaconic acid (3-MGA)) in bodily fluids such as urine and plasma are a hallmark of various metabolic disorders collectively known as 3-Methylglutaconic Aciduria, which involve mitochondrial dysfunction and defects in leucine catabolism.  [7.] 

High concentrations of 3-methylglutaconic acid (3-MGA) can serve as a valuable diagnostic marker and provide insights into the underlying pathophysiology of these conditions.

Mitochondrial disorders, characterized by impaired energy production, are often associated with increased levels of 3-methylglutaconic acid (3-MGA).  [3., 7.]

These disorders can result from genetic defects affecting mitochondrial DNA or nuclear genes encoding mitochondrial proteins, leading to dysfunction in the respiratory chain complexes and oxidative phosphorylation.  

Examples include Leigh syndrome, MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), and MERRF (Myoclonic Epilepsy with Ragged Red Fibers). [5.] 

Additionally, disorders affecting the metabolism of leucine, such as 3-methylglutaconic aciduria types I-VII, can lead to the accumulation of 3-methylglutaconic acid (3-MGA) due to deficiencies in enzymes involved in the leucine catabolic pathway.  

High levels of 3-methylglutaconic acid (3-MGA) can have various clinical manifestations, including developmental delays, seizures, metabolic crises, and neurological impairment, underscoring the importance of early detection and appropriate management.  [3., 5., 6., 7.] 

3-Methylglutaconic Acid Low Levels: What Does Low 3-Methylglutaconic Acid Mean?

While elevated levels of 3-methylglutaconic acid (3-MGA) are associated with various metabolic disorders, low levels of this organic acid are generally not considered clinically significant. 

As a metabolite produced during the breakdown of the amino acid leucine, its presence in bodily fluids at low concentrations is expected in healthy individuals.

3-Methylglutaconic Acid Related Biomarkers

In addition to 3-methylglutaconic acid , several other biomarkers can provide valuable insights into metabolic disorders associated with elevated levels.  These related biomarkers are often analyzed in conjunction with 3-methylglutaconic acid to aid in the differential diagnosis and comprehensive evaluation of these conditions.

Acylcarnitine Profile

Acylcarnitine analysis is a crucial tool in the diagnosis of fatty acid oxidation disorders and organic acidemias. This test measures the levels of various acylcarnitine species in blood or dried blood spots. 

Specific patterns of elevated acylcarnitines can indicate specific enzyme deficiencies or metabolic blocks, complementing the information provided by 3-methylglutaconic acid (3-MGA) levels.

Organic Acid Analysis

Organic acid analysis is a comprehensive test that measures the levels of various organic acids in urine or plasma. This analysis can detect abnormalities in the metabolism of amino acids, fatty acids, and other organic compounds. 

Amino Acid Analysis

Amino acid analysis quantifies the levels of individual amino acids in blood or urine samples. This test can help identify disorders of amino acid metabolism, which may be associated with elevated 3-methylglutaconic acid (3-MGA) levels. For example, abnormalities in the metabolism of leucine, an essential amino acid, can lead to increased production of 3-methylglutaconic acid .

By combining the results of 3-methylglutaconic acid (3-MGA) testing with these related biomarkers, clinicians can gain a more comprehensive understanding of the underlying metabolic disorder, enabling more accurate diagnosis, targeted treatment, and improved patient management.

Order Organic Acids Testing

Click here to compare testing options and order organic acid testing.